Cargando…

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

BACKGROUND: In multiple sclerosis (MS), thalamic integrity is affected directly by demyelination and neuronal loss, and indirectly by gray/white matter lesions outside the thalamus, altering thalamic neuronal projections. OBJECTIVE: To assess the efficacy of ocrelizumab compared with interferon beta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnold, Douglas L, Sprenger, Till, Bar-Or, Amit, Wolinsky, Jerry S, Kappos, Ludwig, Kolind, Shannon, Bonati, Ulrike, Magon, Stefano, van Beek, Johan, Koendgen, Harold, Bortolami, Oscar, Bernasconi, Corrado, Gaetano, Laura, Traboulsee, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493406/ https://www.ncbi.nlm.nih.gov/pubmed/35672926 http://dx.doi.org/10.1177/13524585221097561

Ejemplares similares

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging
por: Kolind, Shannon, et al.
Publicado: (2023)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
por: Bar-Or, Amit, et al.
Publicado: (2023)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set
por: Koch, Marcus W., et al.
Publicado: (2017)

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
por: Wolinsky, Jerry S, et al.
Publicado: (2020)

Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials
por: Orbach, Rotem, et al.
Publicado: (2012)

Hydroxychloroquin könnte die Progression der Behinderung bei PPMS verzögern
por: Menge, Til
Publicado: (2021)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD
por: Samaraweera, Amal P.R., et al.
Publicado: (2018)

A comparison of clinical outcomes in PPMS in the INFORMS original trial data set
por: Koch, Marcus W, et al.
Publicado: (2021)

Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a
por: MacMillan, Erin L, et al.
Publicado: (2019)

Registration Management System (RMS)
por: Epting, U
Publicado: (1999)

Re: CaRMS at 50
por: MacFarlane, Malcolm
Publicado: (2020)

Comprehensive Analysis of PPMs in Pancreatic Adenocarcinoma Indicates the Value of PPM1K in the Tumor Microenvironment
por: Zhuang, Yanyan, et al.
Publicado: (2023)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2019)

EHMTI-0079. Reduced volume of anterior thalamic nuclei in migraineurs
por: Magon, S, et al.
Publicado: (2014)

PPMS: A framework to Profile Primary MicroRNAs from Single-cell RNA-sequencing datasets
por: Ji, Jiahui, et al.
Publicado: (2022)

RMS envelope equations with space charge
por: Sacherer, F J
Publicado: (1970)

RMS envelope equations with space charge
por: Sacherer, Franck J
Publicado: (1971)

Systematic errors on r.m.s. computation
por: Hémery, J-Y
Publicado: (1991)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Development of a Fully Automated, GPS Based Monitoring System for Disaster Prevention and Emergency Preparedness: PPMS(+RT)
por: Bond, Jason, et al.
Publicado: (2007)

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders
por: Engel, Sinah, et al.
Publicado: (2020)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study
por: Magon, Stefano, et al.
Publicado: (2014)

Final setting up cycle of RMS at NIMROD
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1977)

Variable Resistance of RMS to Interferon γ Signaling
por: Simon-Keller, Katja, et al.
Publicado: (2012)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
por: Fox, Edward J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m8dj2uno1jkvmm75d4j2hnlj91